MrMed announces new cold-chain hub in Bengaluru and strategic partnership with Eli Lilly

MrMed, India’s online specialty pharmacy, has announced the launch of its state-of-the-art Bengaluru cold-chain hub, marking a significant advancement in improving access to high-quality specialty medicines across India.

The newly operational cold-chain hub is supporting the safe, seamless delivery of critical therapies including oncology, GLP-1 medications, immunology treatments, and transplant medicines. This development reinforces MrMed’s commitment to strengthening India’s specialty-medicine ecosystem by enhancing availability, affordability, and last-mile accessibility for patients who depend on advanced treatment options.

With diabetes and obesity now affecting over 100 million people in India, the need for reliable access to advanced therapies is more urgent than ever. The MrMed’s Bengaluru cold-chain hub is already reducing delivery timelines within the city while enabling faster dispatches across Karnataka, Tamil Nadu, Telangana, and Kerala.

The startup has also announced a strategic partnership with global healthcare leader Eli Lilly. Through this collaboration, MrMed has strengthened its ability to distribute temperature-sensitive, genuine medicines with greater precision and reliability. Eli Lilly’s global leadership in innovative treatments, combined with MrMed’s expanded cold-chain network, is expected to significantly improve reach, affordability, and continuity of care for patients across India.